Cambium Bio Secures FDA Approval for Single Pivotal Trial Path for Dry Eye Therapy

FDA greenlights single pivotal trial for Cambium Bio’s dry eye therapy

Cambium Bio (ASX: CMB) has received confirmation from the US Food and Drug Administration that a single pivotal clinical study will support the Biologics License Application for Elate Ocular®, its therapy for moderate-to-severe dry eye disease. The confirmation came following a Type D meeting held 22 April 2026 with the FDA’s Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products (OTP), where the Agency stated that one adequate and well-controlled Phase 3 study (CAMOMILE-3), together with confirmatory evidence, represents a reasonable approach to support marketing authorisation.

This decision aligns with the FDA’s updated regulatory policy published 19 February 2026 in the New England Journal of Medicine by FDA officials Dr Vinay Prasad and Dr Martin Makary, which established a single pivotal clinical trial plus confirmatory evidence as the Agency’s new default standard for marketing authorisation, replacing the historical two-trial requirement. For Cambium Bio, this represents a fundamental shift in the regulatory pathway and associated capital requirements for bringing Elate Ocular to market.

What the single-trial pathway means for development costs and timelines

The shift from a two-trial to a one-trial paradigm delivers three material benefits to the development programme. First, it materially reduces clinical development capital requirements by eliminating the need to fund a second pivotal study. Second, it is expected to accelerate patient enrolment by consolidating clinical sites and recruitment efforts into one pivotal Phase 3 programme rather than splitting resources across two concurrent studies competing for the same investigator sites and patient population. Third, it concentrates statistical risk into one well-powered study rather than requiring independent success in two separate pivotal studies, improving the overall probability of generating a successful BLA data package.

Cambium Bio holds Fast Track Designation, granted 4 December 2024, which enables rolling BLA submission. This means sections of the application can be submitted for FDA review as they are completed, rather than waiting for the entire data package to be finalised. The company expects First Patient In later in 2026, setting the stage for progression through topline readout and BLA submission on an accelerated timeframe.

Lower capital burn, faster potential approval, and improved odds of generating a successful BLA package position the company to progress Elate Ocular more efficiently toward commercialisation.

Understanding pivotal trials and BLA submissions

A pivotal clinical trial is the definitive study used to demonstrate a therapy’s safety and efficacy to regulatory authorities. It is designed to provide substantial evidence that a treatment works for its intended patient population under controlled conditions. For biological therapies like Elate Ocular, a Biologics License Application (BLA) is the final regulatory submission to the FDA requesting marketing approval. The BLA includes all clinical trial data, manufacturing information, and proposed labelling for the product.

Historically, the FDA required two independent pivotal trials, each demonstrating statistical significance, to support marketing authorisation. This two-trial standard was based on the principle that replication of results across separate studies provides stronger evidence of efficacy. However, the February 2026 policy shift recognises that a single well-designed pivotal trial, when supported by additional confirmatory evidence, can provide substantial evidence of effectiveness whilst reducing the time and cost required to bring therapies to patients.

Fast Track Designation, which Elate Ocular holds, allows rolling submission of the BLA. Rather than waiting for all components to be finalised, sections can be submitted for review as they are completed. This approach can shorten the overall review timeline and allows the company to supplement the application with confirmatory evidence generated during or after the pivotal study.

Confirmed Phase 3 study design

Trial parameters locked in

The FDA confirmed that the previously agreed Phase 3 design remains acceptable to support the single-trial BLA pathway. The study will be a randomised, double-masked, vehicle-controlled trial enrolling n=400 evaluable subjects treated over a 9-week masked treatment period.

The FDA confirmed two co-primary endpoints for the study:

• Sign endpoint: Corneal Fluorescein Staining Index
• Symptom endpoint: VAS Eye Discomfort Score

Both endpoints must demonstrate statistical significance to support the BLA submission.

Confirmatory evidence strategy

The FDA indicated at the 22 April 2026 meeting that discussion of confirmatory evidence is most appropriate following Phase 3 readout, when the strength of the pivotal clinical data will inform the nature and quantity of confirmatory evidence required. Cambium Bio is evaluating a range of options, including additional product-specific nonclinical studies to support Elate Ocular’s mechanism of action.

Consistent with the September 2023 FDA guidance on demonstrating substantial evidence of effectiveness with one adequate and well-controlled clinical investigation, a range of confirmatory evidence types may be considered. These include mechanistic or pharmacodynamic evidence, evidence from relevant animal models, real-world evidence, and other categories. The specific confirmatory evidence package to be submitted as part of the BLA will be determined in consultation with the FDA following Phase 3 topline data and calibrated to the strength of the pivotal clinical results.

CEO outlines operational focus

Management has emphasised that dry eye disease affects tens of millions of people globally, and treatment options for the moderate-to-severe segment remain limited. The company’s operational priority is now unambiguous: to initiate the single pivotal Phase 3 study as soon as operationally feasible, with First Patient In expected later in 2026, and to drive the programme efficiently toward topline readout and BLA submission.

Karolis Rosickas, Chief Executive Officer

“This represents a substantial acceleration of our development plan, a meaningful reduction in the capital required to reach BLA submission, and an improvement in the overall probability of successfully bringing this therapy to patients in need.”

The confirmation from the FDA removes a key regulatory uncertainty and positions Cambium Bio to execute the pivotal study with clarity on the path to potential marketing approval.

Next steps and investment considerations

The company will now progress through the following operational milestones:

1. Initiate single pivotal Phase 3 study (CAMOMILE-3) with First Patient In later in 2026
2. Conduct Phase 3 with n=400 evaluable subjects over 9-week masked treatment period
3. Generate topline data and discuss confirmatory evidence with FDA
4. Submit rolling BLA under Fast Track Designation

From an investment perspective, the single-trial pathway materially reduces funding requirements versus the two-trial paradigm. The FDA confirmation removes a key regulatory uncertainty, de-risking the development pathway and providing clarity on the route to market. The accelerated timeline, enabled by consolidated patient recruitment and rolling BLA submission, offers a faster path to potential approval. The moderate-to-severe dry eye disease segment, with limited current treatment options, represents a commercially underserved patient population that Elate Ocular is positioned to address.

Want the Next Healthcare Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to get market-moving announcements delivered to your inbox the moment they break.